Liver transplantation for hereditary tyrosinemia type I: Analysis of the UNOS database

Pediatric Transplantation

Volumn 15, Issue 4, 2011, Pages 400-405

  Arnon, Ronen ^a,b   Annunziato, Rachel ^c   Miloh, Tamir ^a,b   Wasserstein, Melissa ^a   Sogawa, Hiroshi ^a   Wilson, Monique ^c   Suchy, Frederick ^a   Kerkar, Nanda ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c FORDHAM UNIVERSITY   (United States)

Author keywords

complications of liver transplantation; congenital liver disease; graft survival; liver transplantation; pediatric transplantation; tyrosinemia

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CHILD; DATA BASE; FEMALE; FULMINANT HEPATIC FAILURE; GRAFT SURVIVAL; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; TREATMENT FAILURE; TYROSINEMIA;

ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TYROSINEMIAS;

EID: 79957480038     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01497.x     Document Type: Article

References (19)

1. Holme E, Lindstedt S,. Diagnosis and management of Tyrosinemia type 1. Curr Opin Pediatr 1995: 7: 716-723.
2. Russo PA, Mitchell GA, Tanguay RM,. Tyrosinemia: A review. Pediatr Dev Pathol 2001: 4: 212-221. (Pubitemid 32423820)
3. Jorquera R, Tanguay RM,. Fumarylacetoacetate, the metabolite accumulating in hereditary Tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001: 10: 1741-1752. (Pubitemid 32899091)
4. Mckiernan PJ,. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006: 66: 743-750. (Pubitemid 43765222)
5. Mohan N, Mckiernan P, Preece MA, et al., Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999: 158 (Suppl 2): S49-S54.
6. Mieles LA, Esquivel CO, Van Thiel DH, et al., Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 1990: 35: 153-157.
7. Pérez-Cerdá C, Merinero B, Sanz P, et al., Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inherit Metab Dis 1995: 18: 119-122.
8. Wijburg FA, Reitsma WC, Slooff MJ, et al., Liver transplantation in tyrosinaemia type I: The Groningen experience. J Inherit Metab Dis 1995: 18: 115-118.
9. Paradis K,. Tyrosinemia: The Quebec experience. Clin Invest Med 1996: 19: 311-316. (Pubitemid 26354108)
10. Arnon R, Kerkar N, Davis MK, Anand R, Yin W, González-Peralta RP,. Liver transplantation in children with metabolic diseases: The studies of pediatric liver transplantation experience. SPLIT Research Group. Pediatr Transplant 2010: 6: 796-805.
11. Kaye CI,; C ommittee on G enetics, Accurso F, et al., Newborn screening fact sheets. Pediatrics 2006: 118: e934-e963. (Pubitemid 46090024)
12. Ashorn M, Pitkänen S, Salo MK, Heikinheimo M,. Current strategies for the treatment of hereditary tyrosinemia type I. Paediatr Drugs 2006: 8: 47-54.
13. Holme E, Lindstedt S,. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000: 4: 805-814.
14. Van Spronsen FJ, Bijleveld CM, Van Maldegem BT, Wijburg FA,. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr 2005: 40: 90-93. (Pubitemid 40180065)
15. Holme E, Lindstedt S,. Tyrosinaemia type I and NTBC (2-(2-nitro-4- trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis 1998: 21: 507-517.
16. Al-Dhalimy M, Overturf K, Finegold M, Grompe M,. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002: 75: 38-45. (Pubitemid 34971533)
17. Poon TC, Yip TT, Chan AT, et al., Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003: 49: 752-760. (Pubitemid 36513254)
18. Pierik LJ, Van Spronsen FJ, Bijleveld CM, Van Dael CM,. Renal function in tyrosinaemia type I after liver transplantation: A long-term follow-up. J Inherit Metab Dis 2005: 28: 871-876. (Pubitemid 43168923)
19. Karakayali H, Ozcay F, Sevmis S, Savas N, Habera M,. Liver transplantation for small babies. Transplant Proc 2007: 39: 1153-1156. (Pubitemid 46764850)